Idera Pharmaceuticals commences phase 1 IMO-2125 clinical trial for chronic HCV infection

Idera Pharmaceuticals, Inc. (Nasdaq: IDRA) today announced that patient treatment has been initiated in a phase 1 clinical trial evaluating IMO-2125 in combination with ribavirin in treatment-naive patients with chronic hepatitis C virus (HCV) infection. IMO-2125 is a novel agonist of Toll-like Receptor (TLR) 9.

“We expect that the IMO-2125 trial with ribavirin in treatment-naïve HCV patients and our ongoing IMO-2125 monotherapy trial in HCV patients who failed to respond to previous standard of care therapy will provide us with data in two HCV patient populations on safety, immunological activity, and effect on HCV RNA levels,” said Tim Sullivan, Ph.D., Vice President of Development Programs. “We plan to use the data from these ongoing trials to guide us in further clinical development of IMO-2125 in the treatment of chronic HCV infection.”

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Chronic cough can be passed down from parents to children, a new study suggests